Zymeworks Inc. - ZYME STOCK NEWS

Zymeworks Inc. (NYSE: ZYME) presented promising clinical data for zanidatamab at the San Antonio Breast Cancer Symposium. In a study of 45 patients with HER2-positive metastatic breast cancer, the combination treatment of zanidatamab, palbociclib, and fulvestrant achieved a confirmed objective response rate (cORR) of 33% and a disease control rate (DCR) of 92%. The median progression-free survival (mPFS) was reported at 9.6 months. The regimen was generally well-tolerated. These results suggest potential for a chemotherapy-free option for heavily pretreated patients.

Zymeworks Inc. (NYSE: ZYME) announced its decision to transfer its stock listing from the New York Stock Exchange to Nasdaq. The stock will cease trading on NYSE at market close on December 15, 2022, and will begin trading on Nasdaq on December 16, 2022, retaining the ticker symbol ZYME. Zymeworks is focused on developing multifunctional biotherapeutics, with lead candidate zanidatamab undergoing multiple clinical trials for HER2-expressing solid tumors.

Zymeworks Inc. (NYSE: ZYME) has announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act regarding its license agreement with Jazz Pharmaceuticals for zanidatamab, a HER2-targeted bispecific antibody. This milestone enables Zymeworks to receive a $50 million non-refundable upfront payment from Jazz, while a potential second payment of $325 million is expected after the readout of clinical data from the HERIZON-BTC-01 study. Zymeworks anticipates sharing the top-line data by the end of 2022.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, will participate in the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2023. Management will hold one-on-one meetings and a fireside chat on November 29 at 4:45 pm EST. Presentations and webcasts will be available on Zymeworks’ website. The company focuses on developing multifunctional biotherapeutics, with lead candidate zanidatamab targeting HER2 in clinical trials.

Zymeworks has announced an exclusive licensing agreement with Jazz Pharmaceuticals for zanidatamab, potentially valued at up to $1.76 billion, including a $50 million upfront payment. This quarter showcased promising Phase 1 trial results for zanidatamab zovodotin, demonstrating a 31% objective response rate in HER2-expressing cancers. Zymeworks has transitioned to a Delaware corporate structure to enhance shareholder value and simplify commercialization. The company reported a decreased net loss of $47.8 million for Q3 2022, down 21% from the prior year, and a cash balance of $166.2 million.

Zymeworks (NYSE: ZYME) held its Early R&D Day to showcase advancements in its pipeline and proprietary technology. The company aims to file five new Investigational New Drug applications over the next five years, emphasizing ongoing research in antibody drug conjugates (ADC) and multi-specific antibody therapeutics (MSAT) targeting cancer. Key updates included data on novel ADCs like ZW191 and ZW251, highlighting the potential to address significant patient needs. Zymeworks is committed to developing innovative therapeutics and advancing its R&D initiatives.

Zymeworks announced an exclusive licensing agreement with Jazz Pharmaceuticals for its HER2-targeted bispecific antibody, zanidatamab. Zymeworks is set to receive an upfront payment of $50 million, with future payments potentially reaching $1.76 billion based on regulatory and commercial milestones. The licensing covers key markets, including the U.S., Europe, and Japan. A conference call will take place today at 8:00 am EST to discuss the partnership and its implications for clinical development.

Jazz Pharmaceuticals has secured exclusive rights to develop and commercialize zanidatamab, a HER2-targeted bispecific antibody, from Zymeworks in major markets including the U.S., Europe, and Japan. Zymeworks will receive an upfront payment of $50 million, with the potential for total payments reaching $1.76 billion upon meeting various milestones. Zanidatamab, currently in pivotal trials for HER2-expressing biliary tract cancer and gastroesophageal adenocarcinoma, has received Breakthrough Therapy designation from the FDA, underscoring its potential in oncology.

Zymeworks Inc. (NYSE: ZYME) will report its third quarter 2022 financial results on November 8, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET, providing insights into financial results and corporate updates. The company specializes in developing multifunctional biotherapeutics, with its lead candidate, zanidatamab, in various clinical trials targeting HER2 in solid tumors. Zymeworks is advancing other candidates including ZW49, a bispecific HER2-targeted antibody-drug conjugate currently in Phase 1.